睿知中国疾病研究地图
候选清单0

即将招募B 细胞急性淋巴细胞白血病I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

U96-CAR-T-Cells For R/R B-ALL

ClinicalTrials.gov 上登记的一项B 细胞急性淋巴细胞白血病开放试验,由苏州大学附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方苏州大学附属第一医院First Affiliated Hospital of Soochow University苏州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07511426,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Bone marrow or peripheral blood or immunohistochemistry or pathology shows CD19 antigen positive;

    入选标准第 11 条

    According to the Lugano Lymphoma Response Evaluation Criteria (Cheson 2014), B-cell lymphoma patients have at least one evaluable lesion, or positive lesions confirmed by PET-CT;

    入选标准第 12 条

  3. According to the "Chinese Adult Acute Lymphoblastic Leukemia Diagnosis and Treatment Guidelines" (2021 Edition), one of the following conditions must be met: a. Refractory leukemia: standard induction therapy fails to achieve CR/CRi after (generally referring to 4-week regimen or Hyper-CVAD regimen) completion; b. Leukemia recurrence: patients who have achieved CR have peripheral blood or bone marrow with blast cells (proportion > 5%) or MRD positive or extramedullary lesions; 2-2) Patients in the B-cell lymphoma group:

    入选标准第 6 条

    Patients with B-cell lymphoma who have failed at least two-line treatment (one standardized chemotherapy regimen + one salvage chemotherapy) or have relapsed before screening. The previous treatment of B-cell lymphoma must include CD20 monoclonal antibody (excluding CD20-negative tumor patients) and anthracycline-based standardized treatment regimen. At least one of the following conditions must be met: a. Unable to undergo autologous hematopoietic stem cell transplantation; b. Refuse to undergo autologous hematopoietic stem cell transplantation; c. Relapse after autologous hematopoietic stem cell transplantation;

    入选标准第 9 条

    The blood/urine pregnancy test for women of childbearing age during the screening period should be negative. Any male or female patient with reproductive capacity must agree to use an effective contraceptive method throughout the study process and for at least 1 year after the administration of the study treatment;

    入选标准第 16 条

  4. Eastern Cooperative Oncology Group (ECOG) performance status score is 0-3;

    入选标准第 13 条

  5. At screening, there is a certain degree of bone marrow reserve, defined as: absolute lymphocyte value (ALC) ≥ 0.3×109/L, platelet (PLT) ≥ 30×109/L (allowing the result after administration);

    入选标准第 14 条

  6. Any of the following conditions: positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab), and the HBV-DNA copy number is greater than the minimum detection limit; positive for hepatitis C antibody (HCV-Ab), and the HCV-RNA copy number is greater than the minimum detection limit; positive for anti-mycoplasma antibody (TP-Ab); positive for human immunodeficiency virus (HIV) antibody;

    排除标准第 3 条

  7. Pregnant or lactating women;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07511426,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. (All the following items must be met simultaneously)
  2. Patients must voluntarily sign the informed consent form and have good compliance;
  3. For different indications, patients must meet the following requirements:
  4. The age at signing the informed consent form is ≥ 18 years old, both male and female are acceptable;
  5. According to the standards of the National Comprehensive Cancer Network (NCCN) Acute Lymphoblastic Leukemia Clinical Practice Guidelines (2024, 2nd Edition), it is clearly diagnosed as acute B lymphoblastic leukemia;
  6. According to the "Chinese Adult Acute Lymphoblastic Leukemia Diagnosis and Treatment Guidelines" (2021 Edition), one of the following conditions must be met: a. Refractory leukemia: standard induction therapy fails to achieve CR/CRi after (generally referring to 4-week regimen or Hyper-CVAD regimen) completion; b. Leukemia recurrence: patients who have achieved CR have peripheral blood or bone marrow with blast cells (proportion > 5%) or MRD positive or extramedullary lesions; 2-2) Patients in the B-cell lymphoma group:
  7. The age at signing the informed consent form is ≥ 18 years old, both male and female are acceptable;
  8. According to the standards of the National Comprehensive Cancer Network (NCCN) B-cell lymphoma clinical practice guidelines (2024, 3rd Edition), it is clearly diagnosed as B-cell lymphoma;
  9. Patients with B-cell lymphoma who have failed at least two-line treatment (one standardized chemotherapy regimen + one salvage chemotherapy) or have relapsed before screening. The previous treatment of B-cell lymphoma must include CD20 monoclonal antibody (excluding CD20-negative tumor patients) and anthracycline-based standardized treatment regimen. At least one of the following conditions must be met: a. Unable to undergo autologous hematopoietic stem cell transplantation; b. Refuse to undergo autologous hematopoietic stem cell transplantation; c. Relapse after autologous hematopoietic stem cell transplantation;
  10. At screening, the patient is in a state of disease recurrence or refractory: a) Recurrence definition: after adequate treatment achieving remission (including partial remission (PR) or complete remission (CR)), PD again occurs; b) Refractoriness definition: i. No response to the last treatment: PD during/after the last treatment or the best efficacy is SD, and the duration is less than 6 months; ii. Recurrence or progression after ASCT (requiring biopsy confirmation), including: recurrence or PD within 12 months after ASCT, if salvage treatment is received, no response (SD or PD) to the last treatment;
  11. Bone marrow or peripheral blood or immunohistochemistry or pathology shows CD19 antigen positive;
  12. According to the Lugano Lymphoma Response Evaluation Criteria (Cheson 2014), B-cell lymphoma patients have at least one evaluable lesion, or positive lesions confirmed by PET-CT;
  13. Eastern Cooperative Oncology Group (ECOG) performance status score is 0-3;
  14. At screening, there is a certain degree of bone marrow reserve, defined as: absolute lymphocyte value (ALC) ≥ 0.3×109/L, platelet (PLT) ≥ 30×109/L (allowing the result after administration);
  15. Have appropriate organ function, and need to meet the following standards: aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) ≤ 3 times ULN (for liver function abnormalities caused by tumor infiltration, AST and ALT ≤ 5 times ULN are required); total serum bilirubin The serum bilirubin should be ≤ 2 times the ULN, except for those with Gilbert syndrome who have a combined condition; the total bilirubin should be ≤ 3 times the ULN and the direct bilirubin should be ≤ 1.5 times the ULN. Patients with Gilbert syndrome who meet these criteria can be included. The serum creatinine should be ≤ 1.5 times the ULN, or the creatinine clearance rate should be ≥ 60 mL/min (Cockcroft and Gault formula); possess the lowest level of pulmonary reserve, defined as ≤ 1 grade of dyspnea and a blood oxygen saturation > 91% in non-oxygenated state; left ventricular ejection fraction of the left heart in echocardiography should be ≥ 50%; International Normalized Ratio (INR) should be ≤ 1.5 times the ULN, and activated partial thromboplastin time (APTT) should be ≤ 1.5 times the ULN;
  16. The blood/urine pregnancy test for women of childbearing age during the screening period should be negative. Any male or female patient with reproductive capacity must agree to use an effective contraceptive method throughout the study process and for at least 1 year after the administration of the study treatment;
  17. The expected survival period should be greater than 3 months.

排除标准:Exclusion Criteria:

  1. (Any of the following conditions will disqualify one from participating)
  2. Having another malignant tumor and the investigator considers that the presence of other malignant tumors may affect the current treatment;
  3. Any of the following conditions: positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc-Ab), and the HBV-DNA copy number is greater than the minimum detection limit; positive for hepatitis C antibody (HCV-Ab), and the HCV-RNA copy number is greater than the minimum detection limit; positive for anti-mycoplasma antibody (TP-Ab); positive for human immunodeficiency virus (HIV) antibody;
  4. Existing bacterial, fungal, viral, mycoplasma or other types of infections and the investigator determines that they are difficult to control;
  5. Having a CNS disease other than this disease in the past or currently, such as epileptic seizures, cerebral ischemia/hemorrhage, dementia, cerebellar disease or any CNS-related autoimmune disease, and the investigator determines that it is uncontrollable;
  6. Before signing the informed consent form, having undergone cardiac angioplasty or stent placement within 12 months, or having NYHA classification III-IV grade congestive heart failure, or having myocardial infarction, unstable angina pectoris or the investigator determines that there is a clinically significant history of heart disease, or the patient's QTc interval is > 480 ms (QTc interval calculated using the Fridericia formula), and the left ventricular ejection fraction of the heart ultrasound is < 50%;
  7. Patients with primary immunodeficiency;
  8. Having had a severe immediate-type hypersensitivity reaction to any drug used in this study;
  9. Having received live vaccines within 6 weeks before screening;
  10. Pregnant or lactating women;
  11. Active autoimmune diseases;
  12. Having active acute or chronic graft-versus-host disease (GVHD) at the time of signing the informed consent form, and the investigator determines that it is uncontrollable;
  13. Participating in any other interventional clinical research within 30 days before signing the informed consent form;
  14. Situations that the investigator deems unsuitable for participating in this study.

引自 ClinicalTrials.gov, NCT07511426, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07511426,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07511426